A dated advertisement
SuperHealthy Rx's offer page lists compounded semaglutide at $85 per month and tirzepatide at $135. Our October 5, 2026 retrieval still showed Labor Day sale language. That mismatch is a reason to verify the current checkout offer, not a basis for inventing a new expiry date. A reader should retain the terms actually presented for the purchase.
What the bundle says
The page describes medical review, medication and shipping together, without a separate membership fee. It presents automatic refills as optional. This is useful information about the advertised payment model, but it does not establish a patient's eligibility, a guaranteed prescription or a future charge under every plan.
What the page cannot prove
The offer refers to an MD Integrations clinician network and licensed U.S. pharmacies. Those descriptions do not identify the specific professional and dispensing pharmacy assigned to an individual order. Request those identities directly. We have not audited the network, inspected a pharmacy or received care through the service.
Trial percentages, testimonials and customer totals are also different evidence categories. A clinical study of an approved medicine should not be read as this provider's independently measured outcome. A customer quotation cannot establish the expected result for everyone purchasing treatment. FDA's distinction between compounded and approved drugs remains relevant even when the ingredient name sounds familiar.
The placement disclosure
Our publisher selected SuperHealthy for the second promotional position, and links may generate compensation. The ordering does not arise from a clinical head-to-head comparison. Use the profile to check the advertised bundle, then direct product suitability and care questions to the licensed professional responsible for treatment.
Source notes
Checked October 5, 2026. Provider pages document advertised terms. Study summaries identify the scope of our review.
- SuperHealthy Rx — GLP-1 offerProvider advertisement
- FDA — concerns with unapproved GLP-1 drugsRegulatory and safety context
- FDA — compounding questions and answersCompounded-product status